Plexxikon commences PLX3397 Phase 2 trial in patients with Hodgkin lymphoma

[News]

Plexxikon today announced that it has treated the first patient in a Phase 2 clinical trial in Hodgkin lymphoma with PLX3397. This novel agent is an oral, selective inhibitor that down-modulates two key cell types that are thought to mediate the progression of Hodgkin lymphoma tumors — macrophages and mast cells.

More... (http://www.news-medical.net/news/20110308/Plexxikon-commences-PLX3397-Phase-2-trial-in-patients-with-Hodgkin-lymphoma.aspx)